Ken Griffin and Stanley Druckenmiller Both Bet Big on Eli Lilly

When two of the sharpest hedge fund minds in the business independently load up on the same stock in the same quarter, retail investors should probably pay attention. That's exactly what happened with Eli Lilly.

Ken Griffin's Citadel Advisors increased its Eli Lilly stake by roughly 291% during the second quarter, according to the fund's latest 13F filing. The position is now worth about $1.1 billion and ranks among Citadel's largest holdings. Stanley Druckenmiller's Duquesne Family Office made a smaller but notable move too, buying 12,380 shares to reopen a position he'd fully exited just a year earlier.

The timing tells its own story. Lilly's shares fell as much as 23% below their previous high by late April before rebounding, meaning both billionaires likely bought into weakness rather than chasing strength — a classic value-investor move on a growth stock.

What drew them in isn't a mystery. Lilly's obesity and diabetes franchise, anchored by Mounjaro and Zepbound, continues to post standout growth. The company's most recent quarter showed revenue of $23.0 billion, up 48% year-over-year, with the weight-loss drugs doing most of the heavy lifting.

Citadel's Eli Lilly stake grew nearly fourfold in a single quarter, making it one of the fund's largest healthcare positions.

For investors watching the ticker (NYSE: LLY), the pipeline is where the next leg of the story gets interesting. Foundayo, a once-daily pill already approved for obesity and awaiting a decision on type 2 diabetes, could open up a much larger patient population that doesn't want injectable treatments. Lilly has also been aggressive on the acquisition front, adding pipeline candidates that extend the growth runway well past the current blockbuster drugs.

It's worth remembering just how dominant Lilly already is in this space. Mounjaro and Zepbound compete directly with Novo Nordisk's Ozempic and Wegovy, and Lilly has consistently posted stronger volume growth in recent quarters as manufacturing capacity has caught up with demand. That competitive positioning is part of what's drawing large, patient capital into the name.

There's a counterpoint worth flagging before anyone piles in based on the 13F headlines alone: hedge fund filings are backward-looking. We don't know the exact price Griffin and Druckenmiller paid, and both could have trimmed or exited since the quarter closed. Following a 13F blindly is a recipe for buying someone else's exit liquidity.

The stock has also already recovered a lot of ground — shares are up a solid single-digit percentage year-to-date after that spring dip, so the window these billionaires may have used to buy at a discount has narrowed.

What makes this more than noise is that Griffin and Druckenmiller don't often converge on the same healthcare name in the same window. Their combined bet reflects genuine conviction that Lilly's obesity-drug dominance has more room to run, not just short-term positioning.

If you're considering LLY, the smarter approach is to treat this 13F activity as a research starting point, not a buy signal on its own. Look at Lilly's next earnings print for Mounjaro and Zepbound volume trends, and watch for the FDA decision timeline on Foundayo's diabetes indication — that's the actual catalyst, not what two billionaires did three months ago.

Position sizing matters here too. Lilly trades at a premium valuation befitting a market leader, so any stumble in obesity-drug growth or a surprise setback in the Foundayo approval timeline could hit the stock harder than a typical pharma name. Investors chasing this trade should treat it as a core long-term healthcare holding, not a short-term momentum play.

Bottom line: smart money is voting for Lilly's obesity franchise with real dollars, but the entry point that made this trade attractive to Griffin and Druckenmiller has already partly closed.